Dyadic International, Inc. (DYAI)
USD 1.21
(-2.26%)
USD 1.21
(-2.26%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.89 Million USD | -1.07% |
| 2022 | 2.93 Million USD | 21.9% |
| 2021 | 2.4 Million USD | 50.06% |
| 2020 | 1.6 Million USD | -4.71% |
| 2019 | 1.68 Million USD | 29.77% |
| 2018 | 1.29 Million USD | 70.81% |
| 2017 | 758.42 Thousand USD | 27.92% |
| 2016 | 592.88 Thousand USD | 87.79% |
| 2015 | 315.71 Thousand USD | -97.48% |
| 2014 | 12.52 Million USD | -26.91% |
| 2013 | 17.13 Million USD | 9.83% |
| 2012 | 15.6 Million USD | 0.0% |
| 2006 | 15.38 Million USD | -3.14% |
| 2005 | 15.88 Million USD | -5.12% |
| 2004 | 16.74 Million USD | 7823.84% |
| 2003 | 211.27 Thousand USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 385.89 Thousand USD | 15.32% |
| 2024 Q1 | 334.61 Thousand USD | -51.26% |
| 2023 FY | 2.89 Million USD | -1.07% |
| 2023 Q1 | 978.05 Thousand USD | 31.51% |
| 2023 Q4 | 686.53 Thousand USD | 72.9% |
| 2023 Q3 | 397.06 Thousand USD | -52.57% |
| 2023 Q2 | 837.15 Thousand USD | -14.41% |
| 2022 Q4 | 743.72 Thousand USD | -15.45% |
| 2022 Q2 | 658.55 Thousand USD | 1.56% |
| 2022 Q1 | 648.42 Thousand USD | 106.97% |
| 2022 FY | 2.93 Million USD | 21.9% |
| 2022 Q3 | 879.59 Thousand USD | 33.57% |
| 2021 Q2 | 937.09 Thousand USD | 103.49% |
| 2021 Q4 | 313.29 Thousand USD | -54.79% |
| 2021 FY | 2.4 Million USD | 50.06% |
| 2021 Q1 | 460.52 Thousand USD | 33.13% |
| 2021 Q3 | 692.92 Thousand USD | -26.06% |
| 2020 Q2 | 524.27 Thousand USD | 66.24% |
| 2020 FY | 1.6 Million USD | -4.71% |
| 2020 Q3 | 416.36 Thousand USD | -20.58% |
| 2020 Q1 | 315.37 Thousand USD | -27.19% |
| 2020 Q4 | 345.91 Thousand USD | -16.92% |
| 2019 Q2 | 390.87 Thousand USD | -2.89% |
| 2019 Q3 | 454.5 Thousand USD | 16.28% |
| 2019 Q4 | 433.16 Thousand USD | -4.69% |
| 2019 FY | 1.68 Million USD | 29.77% |
| 2019 Q1 | 402.52 Thousand USD | -41.4% |
| 2018 Q3 | 262.96 Thousand USD | 63.04% |
| 2018 FY | 1.29 Million USD | 70.81% |
| 2018 Q2 | 161.28 Thousand USD | -12.5% |
| 2018 Q4 | 686.87 Thousand USD | 161.21% |
| 2018 Q1 | 184.33 Thousand USD | 17.41% |
| 2017 Q2 | 207.4 Thousand USD | 70.66% |
| 2017 Q1 | 121.52 Thousand USD | -75.25% |
| 2017 FY | 758.42 Thousand USD | 27.92% |
| 2017 Q3 | 272.49 Thousand USD | 31.38% |
| 2017 Q4 | 157 Thousand USD | -42.38% |
| 2016 Q3 | - USD | -100.0% |
| 2016 Q2 | 14.94 Thousand USD | -82.8% |
| 2016 FY | 592.88 Thousand USD | 87.79% |
| 2016 Q1 | 86.89 Thousand USD | 189.72% |
| 2016 Q4 | 491.05 Thousand USD | 0.0% |
| 2015 FY | 315.71 Thousand USD | -97.48% |
| 2015 Q4 | 29.99 Thousand USD | -85.95% |
| 2015 Q3 | 213.48 Thousand USD | 726.34% |
| 2015 Q2 | 25.83 Thousand USD | -32.28% |
| 2015 Q1 | 38.14 Thousand USD | -99.7% |
| 2014 Q1 | 2.98 Million USD | -27.4% |
| 2014 Q2 | 3.06 Million USD | 2.57% |
| 2014 Q3 | -6.05 Million USD | -297.71% |
| 2014 Q4 | 12.52 Million USD | 307.0% |
| 2014 FY | 12.52 Million USD | -26.91% |
| 2013 Q2 | 7.08 Million USD | 185.31% |
| 2013 Q3 | 3.46 Million USD | -51.13% |
| 2013 Q4 | 4.11 Million USD | 18.82% |
| 2013 FY | 17.13 Million USD | 9.83% |
| 2013 Q1 | 2.48 Million USD | -8.5% |
| 2012 Q2 | 7.84 Million USD | 211.0% |
| 2012 FY | 15.6 Million USD | 0.0% |
| 2012 Q3 | 2.51 Million USD | -67.88% |
| 2012 Q4 | 2.71 Million USD | 7.64% |
| 2012 Q1 | 2.52 Million USD | 0.0% |
| 2006 FY | 15.38 Million USD | -3.14% |
| 2006 Q1 | 3.82 Million USD | -4.84% |
| 2006 Q3 | 4.2 Million USD | 5.93% |
| 2006 Q4 | 3.38 Million USD | -19.53% |
| 2006 Q2 | 3.96 Million USD | 3.76% |
| 2005 Q3 | 4.14 Million USD | 3.81% |
| 2005 Q1 | 3.73 Million USD | -77.69% |
| 2005 FY | 15.88 Million USD | -5.12% |
| 2005 Q4 | 4.02 Million USD | -2.89% |
| 2005 Q2 | 3.98 Million USD | 6.79% |
| 2004 Q3 | - USD | -100.0% |
| 2004 Q4 | 16.74 Million USD | 0.0% |
| 2004 Q2 | 29.86 Thousand USD | -36.37% |
| 2004 Q1 | 46.94 Thousand USD | -77.78% |
| 2004 FY | 16.74 Million USD | 7823.84% |
| 2003 Q3 | - USD | -100.0% |
| 2003 FY | 211.27 Thousand USD | 0.0% |
| 2003 Q1 | 47.81 Thousand USD | 0.0% |
| 2003 Q2 | 40.83 Thousand USD | -14.61% |
| 2003 Q4 | 211.27 Thousand USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Agenus Inc. | 156.31 Million USD | 98.146% |
| Immix Biopharma, Inc. | - USD | -Infinity% |
| Keros Therapeutics, Inc. | 151 Thousand USD | -1819.739% |
| Caribou Biosciences, Inc. | 34.47 Million USD | 91.592% |
| Madrigal Pharmaceuticals, Inc. | - USD | -Infinity% |
| MiMedx Group, Inc. | 321.47 Million USD | 99.098% |
| Novavax, Inc. | 983.7 Million USD | 99.705% |
| Seer, Inc. | 15.18 Million USD | 80.906% |
| Acelyrin, Inc. | - USD | -Infinity% |
| Xeris Biopharma Holdings, Inc. | 163.91 Million USD | 98.232% |
| IO Biotech, Inc. | - USD | -Infinity% |
| Ardelyx, Inc. | 124.45 Million USD | 97.671% |
| C4 Therapeutics, Inc. | 20.75 Million USD | 86.034% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Fortress Biotech, Inc. | 84.51 Million USD | 96.57% |
| Fortress Biotech, Inc. | 84.51 Million USD | 96.57% |
| Geron Corporation | 237 Thousand USD | -1123.125% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 98.796% |
| HOOKIPA Pharma Inc. | 20.12 Million USD | 85.599% |
| Incyte Corporation | 3.69 Billion USD | 99.922% |
| Innoviva, Inc. | 310.46 Million USD | 99.066% |
| Kintara Therapeutics, Inc. | - USD | -Infinity% |
| ChromaDex Corporation | 83.57 Million USD | 96.531% |
| Ligand Pharmaceuticals Incorporated | 131.31 Million USD | 97.792% |
| MEI Pharma, Inc. | 65.29 Million USD | 95.561% |
| NextCure, Inc. | - USD | -Infinity% |
| Onconetix, Inc. | 58.46 Thousand USD | -4858.19% |
| Oncternal Therapeutics, Inc. | 785 Thousand USD | -269.275% |
| GlycoMimetics, Inc. | 10 Thousand USD | -28888.06% |
| IDEAYA Biosciences, Inc. | 23.38 Million USD | 87.604% |
| Vaxcyte, Inc. | - USD | -Infinity% |
| Precigen, Inc. | 6.22 Million USD | 53.433% |
| Pharming Group N.V. | 245.31 Million USD | 98.818% |
| ContextLogic Inc. | 287 Million USD | 98.99% |
| TRACON Pharmaceuticals, Inc. | 12.04 Million USD | 75.934% |
| Pyxis Oncology, Inc. | - USD | -Infinity% |
| Rigel Pharmaceuticals, Inc. | 116.88 Million USD | 97.52% |
| AlloVir, Inc. | - USD | -Infinity% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Marinus Pharmaceuticals, Inc. | 30.98 Million USD | 90.646% |
| Salarius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Summit Therapeutics Inc. | - USD | -Infinity% |
| Syndax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sensei Biotherapeutics, Inc. | - USD | -Infinity% |
| Senti Biosciences, Inc. | 2.56 Million USD | -13.19% |
| BioXcel Therapeutics, Inc. | 1.38 Million USD | -110.058% |
| Alaunos Therapeutics, Inc. | 5000.00 USD | -57876.12% |
| Entrada Therapeutics, Inc. | 129.01 Million USD | 97.753% |
| Psyence Biomedical Ltd. | - USD | -Infinity% |
| Outlook Therapeutics, Inc. | - USD | -Infinity% |
| Chimerix, Inc. | 324 Thousand USD | -794.693% |
| PDS Biotechnology Corporation | - USD | -Infinity% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| CRISPR Therapeutics AG | 371.2 Million USD | 99.219% |
| Wave Life Sciences Ltd. | 113.3 Million USD | 97.442% |
| Phathom Pharmaceuticals, Inc. | 682 Thousand USD | -325.045% |
| Pieris Pharmaceuticals, Inc. | 42.81 Million USD | 93.229% |
| CARGO Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Precision BioSciences, Inc. | 48.72 Million USD | 94.051% |
| Elevation Oncology, Inc. | - USD | -Infinity% |
| Eton Pharmaceuticals, Inc. | 31.64 Million USD | 90.839% |
| Akebia Therapeutics, Inc. | 194.62 Million USD | 98.511% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | 99.841% |
| Aptorum Group Limited | 431.37 Thousand USD | -571.987% |
| Bicycle Therapeutics plc | 26.97 Million USD | 89.254% |
| Telomir Pharmaceuticals, Inc. Common Stock | - USD | -Infinity% |
| Clearside Biomedical, Inc. | 8.22 Million USD | 64.76% |
| Inhibikase Therapeutics, Inc. | 260.5 Thousand USD | -1012.785% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Alkermes plc | 1.66 Billion USD | 99.826% |
| Verrica Pharmaceuticals Inc. | 5.12 Million USD | 43.427% |
| Jaguar Health, Inc. | 9.76 Million USD | 70.302% |
| VistaGen Therapeutics, Inc. | 1.06 Million USD | -172.444% |
| AbCellera Biologics Inc. | 38.02 Million USD | 92.377% |
| PureTech Health plc | 3.33 Million USD | 12.949% |
| TransCode Therapeutics, Inc. | - USD | -Infinity% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | 98.355% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | -261.447% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Aadi Bioscience, Inc. | 24.35 Million USD | 88.097% |
| AnaptysBio, Inc. | 17.15 Million USD | 83.104% |
| eFFECTOR Therapeutics, Inc. | - USD | -Infinity% |
| ESSA Pharma Inc. | - USD | -Infinity% |
| Molecular Templates, Inc. | 57.3 Million USD | 94.942% |
| Scopus BioPharma Inc. | - USD | -Infinity% |
| Sorrento Therapeutics, Inc. | 62.83 Million USD | 95.387% |
| Vaxxinity, Inc. | - USD | -Infinity% |
| Viracta Therapeutics, Inc. | - USD | -Infinity% |
| Sol-Gel Technologies Ltd. | 1.55 Million USD | -86.538% |
| Janux Therapeutics, Inc. | 8.08 Million USD | 64.137% |
| Structure Therapeutics Inc. | - USD | -Infinity% |
| Longboard Pharmaceuticals, Inc. | - USD | -Infinity% |
| Stoke Therapeutics, Inc. | 8.78 Million USD | 66.984% |
| ImmuCell Corporation | 17.47 Million USD | 83.409% |
| Lantern Pharma Inc. | - USD | -Infinity% |
| VYNE Therapeutics Inc. | 424 Thousand USD | -583.681% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 84.782% |
| Opthea Limited | 261.85 Thousand USD | -1007.01% |
| Avidity Biosciences, Inc. | 9.56 Million USD | 69.678% |
| Syros Pharmaceuticals, Inc. | 9.93 Million USD | 70.825% |
| Fate Therapeutics, Inc. | 63.53 Million USD | 95.437% |
| Inhibrx Biosciences, Inc. | 1.8 Million USD | -61.045% |
| Catalyst Pharmaceuticals, Inc. | 398.2 Million USD | 99.272% |
| Orchestra BioMed Holdings, Inc. | 2.76 Million USD | -5.029% |
| Alzamend Neuro, Inc. | - USD | -Infinity% |
| Rocket Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aptose Biosciences Inc. | - USD | -Infinity% |
| ZyVersa Therapeutics, Inc. | - USD | -Infinity% |
| Soligenix, Inc. | 839.35 Thousand USD | -245.359% |
| Century Therapeutics, Inc. | 2.23 Million USD | -29.7% |
| Kura Oncology, Inc. | - USD | -Infinity% |
| TScan Therapeutics, Inc. | 21.04 Million USD | 86.228% |
| Intensity Therapeutics, Inc. | - USD | -Infinity% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 101.21 Million USD | 97.136% |
| Autolus Therapeutics plc | 1.69 Million USD | -70.719% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| EyePoint Pharmaceuticals, Inc. | 46.01 Million USD | 93.701% |
| Eterna Therapeutics Inc. | 68 Thousand USD | -4162.95% |
| Adaptive Biotechnologies Corporation | 170.27 Million USD | 98.298% |
| GRI Bio, Inc. | 21.76 Million USD | 86.683% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | -14.127% |
| Tenaya Therapeutics, Inc. | - USD | -Infinity% |
| IGM Biosciences, Inc. | 2.13 Million USD | -36.094% |
| INmune Bio, Inc. | 155 Thousand USD | -1770.197% |
| Heron Therapeutics, Inc. | 127.04 Million USD | 97.718% |
| SAB Biotherapeutics, Inc. | 2.23 Million USD | -29.469% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Entero Therapeutics, Inc. | - USD | -Infinity% |
| Milestone Pharmaceuticals Inc. | 1 Million USD | -189.881% |
| X4 Pharmaceuticals, Inc. | - USD | -Infinity% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | 66.187% |
| Coherus BioSciences, Inc. | 257.24 Million USD | 98.873% |
| Verastem, Inc. | - USD | -Infinity% |
| Abeona Therapeutics Inc. | 3.5 Million USD | 17.177% |
| Pliant Therapeutics, Inc. | 1.58 Million USD | -83.469% |
| Tonix Pharmaceuticals Holding Corp. | 7.76 Million USD | 62.683% |
| Histogen Inc. | 3.76 Million USD | 23.088% |
| Aprea Therapeutics, Inc. | 583.23 Thousand USD | -397.025% |
| Surrozen, Inc. | - USD | -Infinity% |
| Organovo Holdings, Inc. | 109 Thousand USD | -2559.455% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Ovid Therapeutics Inc. | 391.69 Thousand USD | -640.067% |
| Panbela Therapeutics, Inc. | - USD | -Infinity% |
| CASI Pharmaceuticals, Inc. | 33.87 Million USD | 91.444% |
| Cadrenal Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Centessa Pharmaceuticals plc | 6.85 Million USD | 57.7% |
| Hepion Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arcturus Therapeutics Holdings Inc. | 157.74 Million USD | 98.162% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -1888.207% |
| Apollomics, Inc. | 821 Thousand USD | -253.082% |
| Amarin Corporation plc | 306.91 Million USD | 99.055% |
| Mesoblast Limited | 5.9 Million USD | 50.884% |
| Turnstone Biologics Corp. | 19.3 Million USD | 84.985% |
| Kymera Therapeutics, Inc. | 78.59 Million USD | 96.312% |
| Synaptogenix, Inc. | - USD | -Infinity% |
| Tiziana Life Sciences Ltd | - USD | -Infinity% |
| Aurinia Pharmaceuticals Inc. | 175.51 Million USD | 98.348% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Exelixis, Inc. | 1.83 Billion USD | 99.842% |
| Better Therapeutics, Inc. | - USD | -Infinity% |
| Nurix Therapeutics, Inc. | 76.98 Million USD | 96.235% |
| Apellis Pharmaceuticals, Inc. | 396.59 Million USD | 99.269% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Aridis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Gritstone bio, Inc. | 1.33 Million USD | -117.792% |
| Jasper Therapeutics, Inc. | - USD | -Infinity% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 139.91 Million USD | 97.928% |
| Insmed Incorporated | 305.2 Million USD | 99.05% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| MediWound Ltd. | 18.68 Million USD | 84.487% |
| OmniAb, Inc. | 34.16 Million USD | 91.515% |
| Alector, Inc. | 97.06 Million USD | 97.013% |
| Seres Therapeutics, Inc. | 126.32 Million USD | 97.705% |
| Checkpoint Therapeutics, Inc. | 103 Thousand USD | -2714.375% |
| Zai Lab Limited | 266.71 Million USD | 98.913% |
| Revance Therapeutics, Inc. | 234.04 Million USD | 98.761% |
| Aura Biosciences, Inc. | - USD | -Infinity% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -2129.851% |
| Immunic, Inc. | - USD | -Infinity% |
| Tarsus Pharmaceuticals, Inc. | 17.44 Million USD | 83.385% |
| Veracyte, Inc. | 361.05 Million USD | 99.197% |
| InMed Pharmaceuticals Inc. | 4.59 Million USD | 36.951% |
| FibroGen, Inc. | 147.75 Million USD | 98.038% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| Adial Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sonnet BioTherapeutics Holdings, Inc. | 147.8 Thousand USD | -1861.237% |
| Jazz Pharmaceuticals plc | 3.83 Billion USD | 99.924% |
| Cyclacel Pharmaceuticals, Inc. | 420 Thousand USD | -590.192% |
| Amylyx Pharmaceuticals, Inc. | 380.78 Million USD | 99.239% |
| TG Therapeutics, Inc. | 233.66 Million USD | 98.759% |
| Galecto, Inc. | - USD | -Infinity% |
| Calithera Biosciences, Inc. | - USD | -Infinity% |
| Fortrea Holdings Inc. | 3.1 Billion USD | 99.907% |
| KalVista Pharmaceuticals, Inc. | - USD | -Infinity% |
| Aptevo Therapeutics Inc. | - USD | -Infinity% |
| XBiotech Inc. | - USD | -Infinity% |
| Jasper Therapeutics, Inc. | - USD | -Infinity% |
| Lyra Therapeutics, Inc. | 1.55 Million USD | -86.059% |
| Foghorn Therapeutics Inc. | 34.15 Million USD | 91.513% |
| Y-mAbs Therapeutics, Inc. | 84.81 Million USD | 96.582% |
| Theravance Biopharma, Inc. | 57.42 Million USD | 94.952% |
| Ultragenyx Pharmaceutical Inc. | 434.24 Million USD | 99.332% |
| Metagenomi, Inc. Common Stock | 44.75 Million USD | 93.523% |
| BioCryst Pharmaceuticals, Inc. | 331.41 Million USD | 99.125% |
| Gain Therapeutics, Inc. | 55.18 Thousand USD | -5153.364% |
| Cartesian Therapeutics, Inc. | 26 Million USD | 88.852% |
| NexImmune, Inc. | - USD | -Infinity% |
| Creative Medical Technology Holdings, Inc. | 9000.00 USD | -32108.956% |
| Marker Therapeutics, Inc. | 3.31 Million USD | 12.453% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 99.978% |
| Chemomab Therapeutics Ltd. | - USD | -Infinity% |
| RAPT Therapeutics, Inc. | - USD | -Infinity% |
| Ainos, Inc. | 122.11 Thousand USD | -2273.891% |
| Pluri Inc. | 326 Thousand USD | -789.204% |
| Prothena Corporation plc | 91.37 Million USD | 96.827% |
| Adaptimmune Therapeutics plc | 60.28 Million USD | 95.191% |
| Celularity Inc. | 22.77 Million USD | 87.27% |
| Rallybio Corporation | - USD | -Infinity% |
| Cue Biopharma, Inc. | 5.49 Million USD | 47.198% |
| MeiraGTx Holdings plc | 14.01 Million USD | 79.319% |
| Omeros Corporation | - USD | -Infinity% |
| Humacyte, Inc. | - USD | -Infinity% |
| Immunocore Holdings plc | 249.42 Million USD | 98.838% |
| Cocrystal Pharma, Inc. | - USD | -Infinity% |
| Cidara Therapeutics, Inc. | 63.9 Million USD | 95.464% |
| Blueprint Medicines Corporation | 249.38 Million USD | 98.838% |
| CalciMedica, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | - USD | -Infinity% |
| Scholar Rock Holding Corporation | - USD | -Infinity% |
| Sana Biotechnology, Inc. | - USD | -Infinity% |
| Pulmatrix, Inc. | 7.29 Million USD | 60.279% |
| Elicio Therapeutics, Inc. | - USD | -Infinity% |
| Vigil Neuroscience, Inc. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | 92.009% |
| Adlai Nortye Ltd. American Depositary Shares | 4.99 Million USD | 41.973% |
| Cytokinetics, Incorporated | 7.53 Million USD | 61.503% |
| Eloxx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 2.08 Million USD | -39.011% |
| Protara Therapeutics, Inc. | - USD | -Infinity% |
| Vor Biopharma Inc. | - USD | -Infinity% |
| Roivant Sciences Ltd. | 124.79 Million USD | 97.677% |
| Evogene Ltd. | 5.64 Million USD | 48.603% |
| ProKidney Corp. | - USD | -Infinity% |
| Applied Therapeutics, Inc. | 9.99 Million USD | 70.992% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| BridgeBio Pharma, Inc. | 9.3 Million USD | 68.84% |
| CorMedix Inc. | - USD | -Infinity% |
| BioLineRx Ltd. | 4.8 Million USD | 39.608% |
| Tango Therapeutics, Inc. | 36.52 Million USD | 92.064% |
| Galectin Therapeutics Inc. | - USD | -Infinity% |
| Atai Life Sciences N.V. | 314 Thousand USD | -823.187% |
| Renovaro Biosciences Inc. | - USD | -Infinity% |
| Aerovate Therapeutics, Inc. | - USD | -Infinity% |
| Zentalis Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sagimet Biosciences Inc. | 2 Million USD | -44.94% |
| MediciNova, Inc. | 1 Million USD | -189.881% |
| Praxis Precision Medicines, Inc. | 2.44 Million USD | -18.464% |
| Cardio Diagnostics Holdings, Inc. | 17.06 Thousand USD | -16886.85% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | 98.929% |
| Biomea Fusion, Inc. | - USD | -Infinity% |
| PTC Therapeutics, Inc. | 937.82 Million USD | 99.691% |
| Mereo BioPharma Group plc | 10 Million USD | 71.012% |
| Cullinan Oncology, Inc. | - USD | -Infinity% |
| Absci Corporation | 5.71 Million USD | 49.304% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| 4D Molecular Therapeutics, Inc. | 20.72 Million USD | 86.012% |
| Dyne Therapeutics, Inc. | - USD | -Infinity% |
| Kiniksa Pharmaceuticals, Ltd. | 270.25 Million USD | 98.927% |
| Ventyx Biosciences, Inc. | - USD | -Infinity% |
| Allakos Inc. | - USD | -Infinity% |
| Imunon, Inc. | - USD | -Infinity% |
| Fulcrum Therapeutics, Inc. | 2.8 Million USD | -3.344% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | 99.399% |
| BioAtla, Inc. | - USD | -Infinity% |
| NLS Pharmaceutics AG | - USD | -Infinity% |
| Bio-Path Holdings, Inc. | - USD | -Infinity% |
| Allogene Therapeutics, Inc. | 95 Thousand USD | -2951.375% |
| Larimar Therapeutics, Inc. | - USD | -Infinity% |
| XOMA Corporation | 4.75 Million USD | 39.075% |
| Kezar Life Sciences, Inc. | 7 Million USD | 58.588% |
| Cara Therapeutics, Inc. | 20.96 Million USD | 86.175% |
| aTyr Pharma, Inc. | 353 Thousand USD | -721.192% |
| Aligos Therapeutics, Inc. | 15.52 Million USD | 81.333% |
| Akero Therapeutics, Inc. | - USD | -Infinity% |
| Viridian Therapeutics, Inc. | 314 Thousand USD | -823.187% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| EyeGate Pharmaceuticals, Inc. | 12.05 Thousand USD | -23938.527% |
| Akari Therapeutics, Plc | - USD | -Infinity% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | 99.65% |
| Lexaria Bioscience Corp. | 226.2 Thousand USD | -1181.478% |
| UroGen Pharma Ltd. | 82.71 Million USD | 96.495% |
| Sutro Biopharma, Inc. | 153.73 Million USD | 98.114% |
| ZIVO Bioscience, Inc. | 27.65 Thousand USD | -10383.928% |
| Orgenesis Inc. | 530 Thousand USD | -446.945% |
| Entera Bio Ltd. | - USD | -Infinity% |
| GH Research PLC | - USD | -Infinity% |
| Lisata Therapeutics, Inc. | - USD | -Infinity% |
| Reneo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Xencor, Inc. | 168.33 Million USD | 98.278% |
| 60 Degrees Pharmaceuticals, Inc. | 253.57 Thousand USD | -1043.184% |
| Replimune Group, Inc. | - USD | -Infinity% |
| Coeptis Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Vanda Pharmaceuticals Inc. | 192.64 Million USD | 98.495% |
| Lexaria Bioscience Corp. | 226.2 Thousand USD | -1181.478% |
| Portage Biotech Inc. | - USD | -Infinity% |
| Cardio Diagnostics Holdings, Inc. | 17.06 Thousand USD | -16886.85% |
| Olema Pharmaceuticals, Inc. | - USD | -Infinity% |
| OncoCyte Corporation | 1.5 Million USD | -92.868% |
| Qualigen Therapeutics, Inc. | 5.2 Million USD | 44.305% |
| Processa Pharmaceuticals, Inc. | - USD | -Infinity% |
| Purple Biotech Ltd. | - USD | -Infinity% |
| CollPlant Biotechnologies Ltd. | 10.95 Million USD | 73.549% |
| scPharmaceuticals Inc. | 13.59 Million USD | 78.674% |
| ProMIS Neurosciences, Inc. | - USD | -Infinity% |
| HilleVax, Inc. | - USD | -Infinity% |
| NeuroSense Therapeutics Ltd. | - USD | -Infinity% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Atossa Therapeutics, Inc. | - USD | -Infinity% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | - USD | -Infinity% |
| Savara Inc. | - USD | -Infinity% |
| Curis, Inc. | 10.02 Million USD | 71.078% |
| Daré Bioscience, Inc. | 2.8 Million USD | -3.238% |
| Carmell Therapeutics Corporation | - USD | -Infinity% |
| Titan Pharmaceuticals, Inc. | 184 Thousand USD | -1475.438% |
| Achieve Life Sciences, Inc. | - USD | -Infinity% |
| BeiGene, Ltd. | 2.45 Billion USD | 99.882% |
| Kiromic BioPharma, Inc. | - USD | -Infinity% |
| Revolution Medicines, Inc. Warrant | 11.58 Million USD | 74.967% |
| Protagonist Therapeutics, Inc. | 60 Million USD | 95.169% |
| Erasca, Inc. | - USD | -Infinity% |
| bluebird bio, Inc. | 29.49 Million USD | 90.173% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 99.88% |
| DBV Technologies S.A. | 15.72 Million USD | 81.569% |
| Protagenic Therapeutics, Inc. | - USD | -Infinity% |
| Moderna, Inc. | 6.84 Billion USD | 99.958% |
| Vincerx Pharma, Inc. | - USD | -Infinity% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 63.792% |
| Acrivon Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Travere Therapeutics, Inc. | 145.23 Million USD | 98.004% |
| Monte Rosa Therapeutics, Inc. | - USD | -Infinity% |
| Spruce Biosciences, Inc. | 10.08 Million USD | 71.268% |
| Celldex Therapeutics, Inc. | 6.88 Million USD | 57.885% |
| Cogent Biosciences, Inc. | - USD | -Infinity% |
| MacroGenics, Inc. | 58.74 Million USD | 95.066% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Prime Medicine, Inc. | - USD | -Infinity% |
| Aditxt, Inc. | 645.17 Thousand USD | -349.305% |
| Adagene Inc. | 18.11 Million USD | 83.995% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 1.08 Million USD | -167.912% |
| Maravai LifeSciences Holdings, Inc. | 288.94 Million USD | 98.997% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 250 Million USD | 98.841% |
| SciSparc Ltd. | 2.87 Million USD | -0.688% |
| Vericel Corporation | 197.51 Million USD | 98.532% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Minerva Neurosciences, Inc. | - USD | -Infinity% |
| Generation Bio Co. | 5.9 Million USD | 50.901% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | - USD | -Infinity% |
| Arcutis Biotherapeutics, Inc. | 59.6 Million USD | 95.137% |
| Invivyd, Inc. | - USD | -Infinity% |
| Relay Therapeutics, Inc. | 25.54 Million USD | 88.653% |
| Quoin Pharmaceuticals, Ltd. | - USD | -Infinity% |
| Spero Therapeutics, Inc. | 96.73 Million USD | 97.003% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 100.38 Million USD | 97.112% |
| ADMA Biologics, Inc. | 258.21 Million USD | 98.877% |
| Clene Inc. | 654 Thousand USD | -343.243% |
| Capricor Therapeutics, Inc. | 25.17 Million USD | 88.487% |
| Boundless Bio, Inc. Common Stock | - USD | -Infinity% |
| GeoVax Labs, Inc. | - USD | -Infinity% |
| Recursion Pharmaceuticals, Inc. | 44.57 Million USD | 93.497% |
| Citius Pharmaceuticals, Inc. | - USD | -Infinity% |
| Contineum Therapeutics, Inc. Class A Common Stock | 50 Million USD | 94.202% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| Finch Therapeutics Group, Inc. | 107 Thousand USD | -2609.164% |
| ALX Oncology Holdings Inc. | - USD | -Infinity% |
| Vir Biotechnology, Inc. | 86.18 Million USD | 96.636% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -3864.884% |
| Ocular Therapeutix, Inc. | 58.44 Million USD | 95.04% |
| Verve Therapeutics, Inc. | 11.75 Million USD | 75.346% |
| Trevena, Inc. | 3.12 Million USD | 7.238% |
| Surrozen, Inc. | - USD | -Infinity% |
| Tyra Biosciences, Inc. | - USD | -Infinity% |
| Cingulate Inc. | - USD | -Infinity% |
| Galmed Pharmaceuticals Ltd. | - USD | -Infinity% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| Tenax Therapeutics, Inc. | - USD | -Infinity% |
| Terns Pharmaceuticals, Inc. | - USD | -Infinity% |
| ACADIA Pharmaceuticals Inc. | 726.43 Million USD | 99.601% |
| Connect Biopharma Holdings Limited | - USD | -Infinity% |
| Clearmind Medicine Inc. | - USD | -Infinity% |
| Kronos Bio, Inc. | 6.28 Million USD | 53.899% |
| Bolt Biotherapeutics, Inc. | 7.87 Million USD | 63.194% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Statera Biopharma, Inc. | - USD | -Infinity% |
| ImmunityBio, Inc. | 622 Thousand USD | -366.046% |
| Korro Bio, Inc. | - USD | -Infinity% |
| Kineta, Inc. | 5.44 Million USD | 46.733% |
| BioVie Inc. | - USD | -Infinity% |
| Codexis, Inc. | 70.14 Million USD | 95.867% |
| Celularity Inc. | 22.77 Million USD | 87.27% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | 27.765% |
| Celcuity Inc. | - USD | -Infinity% |
| Virax Biolabs Group Limited | 156.41 Thousand USD | -1753.231% |
| Cibus, Inc. | 1.81 Million USD | -59.538% |
| Eledon Pharmaceuticals, Inc. | - USD | -Infinity% |
| IN8bio, Inc. | - USD | -Infinity% |
| Kodiak Sciences Inc. | - USD | -Infinity% |
| Annexon, Inc. | - USD | -Infinity% |
| Adverum Biotechnologies, Inc. | 3.6 Million USD | 19.478% |
| Assembly Biosciences, Inc. | 7.16 Million USD | 59.531% |
| Avalo Therapeutics, Inc. | 1.92 Million USD | -50.666% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | 99.632% |
| Eyenovia, Inc. | 3787.00 USD | -76446.237% |
| Puma Biotechnology, Inc. | 235.63 Million USD | 98.77% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Xilio Therapeutics, Inc. | - USD | -Infinity% |
| Arcellx, Inc. | 110.31 Million USD | 97.372% |
| Cardiff Oncology, Inc. | 488 Thousand USD | -494.018% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 96.34% |
| Regulus Therapeutics Inc. | - USD | -Infinity% |
| Moolec Science SA | 905.04 Thousand USD | -220.293% |
| Acumen Pharmaceuticals, Inc. | - USD | -Infinity% |
| LAVA Therapeutics N.V. | 6.76 Million USD | 57.175% |
| Royalty Pharma plc | 2.35 Billion USD | 99.877% |
| Atea Pharmaceuticals, Inc. | - USD | -Infinity% |
| Greenwich LifeSciences, Inc. | - USD | -Infinity% |
| TFF Pharmaceuticals, Inc. | 733.87 Thousand USD | -295.002% |
| Mersana Therapeutics, Inc. | 36.85 Million USD | 92.135% |
| Humacyte, Inc. | - USD | -Infinity% |
| 89bio, Inc. | - USD | -Infinity% |
| PMV Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | 170 Thousand USD | -1605.18% |
| Trevi Therapeutics, Inc. | - USD | -Infinity% |
| Lexicon Pharmaceuticals, Inc. | 1.2 Million USD | -140.765% |
| Notable Labs, Ltd. | 310 Thousand USD | -835.099% |
| Liquidia Corporation | 17.48 Million USD | 83.424% |
| Mustang Bio, Inc. | - USD | -Infinity% |
| Immunovant, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 1.08 Million USD | -167.912% |
| Arbutus Biopharma Corporation | 18.14 Million USD | 84.021% |
| DiaMedica Therapeutics Inc. | - USD | -Infinity% |
| Vera Therapeutics, Inc. | 1.86 Million USD | -55.682% |
| Acasti Pharma Inc. | - USD | -Infinity% |
| MiNK Therapeutics, Inc. | - USD | -Infinity% |
| Pasithea Therapeutics Corp. | - USD | -Infinity% |
| Xenon Pharmaceuticals Inc. | - USD | -Infinity% |
| Elevai Labs, Inc. Common Stock | 1.71 Million USD | -69.264% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Tempest Therapeutics, Inc. | - USD | -Infinity% |
| Soleno Therapeutics, Inc. | - USD | -Infinity% |
| PepGen Inc. | - USD | -Infinity% |
| Moleculin Biotech, Inc. | - USD | -Infinity% |
| United Therapeutics Corporation | 2.32 Billion USD | 99.875% |
| Nuvectis Pharma, Inc. | - USD | -Infinity% |
| Solid Biosciences Inc. | - USD | -Infinity% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Immuneering Corporation | - USD | -Infinity% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Silo Pharma, Inc. | 72.1 Thousand USD | -3920.424% |
| Belite Bio, Inc | - USD | -Infinity% |
| XOMA Corporation | 4.75 Million USD | 39.075% |
| ARS Pharmaceuticals, Inc. | 30 Thousand USD | -9562.687% |
| Bionomics Limited | - USD | -Infinity% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| Alpha Tau Medical Ltd. | - USD | -Infinity% |
| uniQure N.V. | 15.84 Million USD | 81.703% |
| Cassava Sciences, Inc. | - USD | -Infinity% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | 64.7 Million USD | 95.52% |
| Forte Biosciences, Inc. | - USD | -Infinity% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | - USD | -Infinity% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | - USD | -Infinity% |
| Altimmune, Inc. | 426 Thousand USD | -580.471% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | 99.274% |
| Alpha Tau Medical Ltd. | - USD | -Infinity% |
| Compugen Ltd. | 33.45 Million USD | 91.336% |
| Peak Bio, Inc. | 367.87 Thousand USD | -687.982% |
| Zevra Therapeutics, Inc. | 27.46 Million USD | 89.444% |
| Benitec Biopharma Inc. | 216 Thousand USD | -1242.04% |
| Spyre Therapeutics, Inc. | 886 Thousand USD | -227.179% |
| NKGen Biotech, Inc. Common Stock | - USD | -Infinity% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | - USD | -Infinity% |
| Aileron Therapeutics, Inc. | - USD | -Infinity% |
| NKGen Biotech, Inc. Warrants | - USD | -Infinity% |
| Instil Bio, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 99.764% |
| Immunome, Inc. | 14.01 Million USD | 79.321% |
| Compass Therapeutics, Inc. | - USD | -Infinity% |
| Verona Pharma plc | - USD | -Infinity% |
| enGene Holdings Inc. Warrants | - USD | -Infinity% |
| Shattuck Labs, Inc. | 1.65 Million USD | -74.943% |
| CervoMed Inc. | 7.14 Million USD | 59.428% |
| LENZ Therapeutics, Inc. | - USD | -Infinity% |
| Plus Therapeutics, Inc. | 4.91 Million USD | 40.997% |
| Dianthus Therapeutics, Inc. | 2.82 Million USD | -2.576% |
| Moolec Science SA | 905.04 Thousand USD | -220.293% |
| Enveric Biosciences, Inc. | - USD | -Infinity% |
| Inovio Pharmaceuticals, Inc. | 832.01 Thousand USD | -248.41% |
| Design Therapeutics, Inc. | - USD | -Infinity% |
| Leap Therapeutics, Inc. | - USD | -Infinity% |
| NeurAxis, Inc. | 2.46 Million USD | -17.835% |
| Seelos Therapeutics, Inc. | 2.2 Million USD | -31.584% |
| Lumos Pharma, Inc. | 2.05 Million USD | -41.336% |
| Achilles Therapeutics plc | - USD | -Infinity% |
| enGene Holdings Inc. Common Stock | - USD | -Infinity% |
| 180 Life Sciences Corp. | - USD | -Infinity% |
| Opiant Pharmaceuticals, Inc. | 40.72 Million USD | 92.882% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Nutriband Inc. | 2.08 Million USD | -39.011% |
| ORIC Pharmaceuticals, Inc. | - USD | -Infinity% |
| CG Oncology, Inc. Common stock | 204 Thousand USD | -1320.983% |
| Fractyl Health, Inc. Common Stock | 120 Thousand USD | -2315.672% |
| Rani Therapeutics Holdings, Inc. | - USD | -Infinity% |
| MoonLake Immunotherapeutics | - USD | -Infinity% |
| Palisade Bio, Inc. | 250 Thousand USD | -1059.522% |
| Tourmaline Bio, Inc. | - USD | -Infinity% |
| Beam Therapeutics Inc. | 377.7 Million USD | 99.233% |
| Neurogene Inc. | - USD | -Infinity% |
| Mirum Pharmaceuticals, Inc. | 186.37 Million USD | 98.445% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| Sesen Bio, Inc. | 40 Million USD | 92.753% |
| Enliven Therapeutics, Inc. | - USD | -Infinity% |
| Kiora Pharmaceuticals, Inc. | - USD | -Infinity% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -143.802% |
| Taysha Gene Therapies, Inc. | 15.45 Million USD | 81.239% |
| Athira Pharma, Inc. | - USD | -Infinity% |
| Vaccinex, Inc. | 570 Thousand USD | -408.562% |
| HCW Biologics Inc. | 2.84 Million USD | -2.006% |
| XOMA Corporation | 4.75 Million USD | 39.075% |
| Nektar Therapeutics | 90.12 Million USD | 96.783% |
| Arvinas, Inc. | 78.5 Million USD | 96.307% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Merus N.V. | 43.94 Million USD | 93.404% |
| Omega Therapeutics, Inc. | 3.09 Million USD | 6.309% |
| Quince Therapeutics, Inc. | - USD | -Infinity% |
| Rezolute, Inc. | - USD | -Infinity% |
| Clene Inc. | 654 Thousand USD | -343.243% |
| Indaptus Therapeutics, Inc. | - USD | -Infinity% |
| BeyondSpring Inc. | 1.75 Million USD | -65.551% |
| Synlogic, Inc. | 3.37 Million USD | 14.008% |
| Allarity Therapeutics, Inc. | - USD | -Infinity% |
| Phio Pharmaceuticals Corp. | - USD | -Infinity% |
| Peak Bio, Inc. | 367.87 Thousand USD | -687.982% |
| Werewolf Therapeutics, Inc. | 19.94 Million USD | 85.465% |
| Krystal Biotech, Inc. | 50.69 Million USD | 94.282% |
| Karyopharm Therapeutics Inc. | 146.03 Million USD | 98.015% |
| SpringWorks Therapeutics, Inc. | 5.44 Million USD | 46.782% |
| Lipella Pharmaceuticals Inc. | 449.61 Thousand USD | -544.728% |
| MannKind Corporation | 198.96 Million USD | 98.543% |
| Ikena Oncology, Inc. | 9.16 Million USD | 68.354% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 113.45 Million USD | 97.445% |
| Gossamer Bio, Inc. | - USD | -Infinity% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | - USD | -Infinity% |
| NRx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Legend Biotech Corporation | 285.14 Million USD | 98.983% |
| Mural Oncology plc | - USD | -Infinity% |
| Biora Therapeutics, Inc. | 4000.00 USD | -72370.15% |
| PaxMedica, Inc. Common Stock | - USD | -Infinity% |
| Disc Medicine, Inc. | - USD | -Infinity% |
| Champions Oncology, Inc. | 50.15 Million USD | 94.22% |
| REGENXBIO Inc. | 90.24 Million USD | 96.788% |
| Ensysce Biosciences, Inc. | 2.23 Million USD | -29.961% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | - USD | -Infinity% |
| Edgewise Therapeutics, Inc. | - USD | -Infinity% |
| Vaxart, Inc. | 7.37 Million USD | 60.715% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | - USD | -Infinity% |
| Cellectis S.A. | 755 Thousand USD | -283.948% |
| Longeveron Inc. | 709 Thousand USD | -308.858% |
| Repare Therapeutics Inc. | 51.13 Million USD | 94.331% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | 99.767% |
| Inozyme Pharma, Inc. | - USD | -Infinity% |
| Revolution Medicines, Inc. | 11.58 Million USD | 74.967% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | - USD | -Infinity% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 210 Thousand USD | -1280.384% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 99.971% |
| Denali Therapeutics Inc. | 330.53 Million USD | 99.123% |
| Revelation Biosciences, Inc. | - USD | -Infinity% |
| Veru Inc. | 16.29 Million USD | 82.213% |
| Corvus Pharmaceuticals, Inc. | - USD | -Infinity% |
| Cingulate Inc. | - USD | -Infinity% |
| Passage Bio, Inc. | - USD | -Infinity% |
| Context Therapeutics Inc. | - USD | -Infinity% |
| Exicure, Inc. | - USD | -Infinity% |
| Day One Biopharmaceuticals, Inc. | - USD | -Infinity% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | -7.244% |
| Scinai Immunotherapeutics Ltd. | - USD | -Infinity% |
| Rhythm Pharmaceuticals, Inc. | 77.42 Million USD | 96.256% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | 152.43 Thousand USD | -1801.729% |
| Carisma Therapeutics, Inc. | 14.91 Million USD | 80.57% |
| Unicycive Therapeutics, Inc. | 675 Thousand USD | -329.453% |
| OmniAb, Inc. | 34.16 Million USD | 91.515% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 21.25 Million USD | 86.36% |
| Lipocine Inc. | -2.85 Million USD | 201.683% |
| Lexeo Therapeutics, Inc. Common Stock | - USD | -Infinity% |
| Nautilus Biotechnology, Inc. | - USD | -Infinity% |
| SAB Biotherapeutics, Inc. | 2.23 Million USD | -29.469% |
| G1 Therapeutics, Inc. | 82.51 Million USD | 96.487% |
| Bellerophon Therapeutics, Inc. | - USD | -Infinity% |
| Sage Therapeutics, Inc. | 86.45 Million USD | 96.647% |
| Ocugen, Inc. | 6.03 Million USD | 51.975% |
| Mind Medicine (MindMed) Inc. | - USD | -Infinity% |
| Q32 Bio Inc. | 1.15 Million USD | -150.762% |
| Brainstorm Cell Therapeutics Inc. | - USD | -Infinity% |
| Alumis Inc. Common Stock | - USD | -Infinity% |
| Equillium, Inc. | 36.08 Million USD | 91.967% |
| Kyverna Therapeutics, Inc. | - USD | -Infinity% |
| Coya Therapeutics, Inc. | 6 Million USD | 51.704% |
| CNS Pharmaceuticals, Inc. | - USD | -Infinity% |
| Galera Therapeutics, Inc. | - USD | -Infinity% |
| Evelo Biosciences, Inc. | - USD | -Infinity% |
| Comera Life Sciences Holdings, Inc. | 633.1 Thousand USD | -357.873% |
| Dominari Holdings Inc. | 2.03 Million USD | -42.168% |
| Edesa Biotech, Inc. | - USD | -Infinity% |
| vTv Therapeutics Inc. | - USD | -Infinity% |
| Bio-Techne Corporation | 1.15 Billion USD | 99.75% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | 89.193% |
| Harmony Biosciences Holdings, Inc. | 582.02 Million USD | 99.502% |
| Prelude Therapeutics Incorporated | - USD | -Infinity% |
| Candel Therapeutics, Inc. | - USD | -Infinity% |
| iTeos Therapeutics, Inc. | 12.59 Million USD | 76.984% |
| Nkarta, Inc. | - USD | -Infinity% |
| BioCardia, Inc. | 477 Thousand USD | -507.716% |
| Iterum Therapeutics plc | - USD | -Infinity% |